RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Benzinga · 1d ago
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $259 to $260.